Synovial Sarcoma Market

DelveInsight’s ‘Synovial Sarcoma (SyS)—Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of and historical and forecasted epidemiology as well as the market trends of synovial sarcoma in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.


The synovial sarcoma market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted synovial sarcoma symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current synovial sarcoma symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Synovial Sarcoma Disease Understanding and Treatment Algorithm

Synovial Sarcoma Overview

Synovial sarcoma (SyS), which may also be called malignant synovioma, is cancer that can originate from different types of soft tissue, such as muscle or ligaments. It is often found in the arm, leg, or foot and near joints such as the wrist or ankle. It can also form in soft tissues in the lung or abdomen.


On a pathology report, synovial sarcoma may be classified into different subtypes depending on what it looks like under the microscope or what specific gene mutation is involved. Synovial sarcoma is a high-grade tumor. It spreads to distant sites in up to 50% of cases. The symptoms caused by synovial sarcoma depend on where the tumor forms. It is often first noticed as a painless lump. If it is near a nerve, it might cause pain or numbness as it grows.


SyS has unique pathologic and genomic characteristics, including histologic subtypes, biphasic and monophasic, and a characteristic translocation, t(X; 18) (p11.2; q11.2). This translocation is believed to be an early event, as the fusion type is concordant in primary tumors and metastases and constant throughout the disease. It occurs in more than 95% of the synovial sarcomas, making it a frequently used diagnostic criterion. Other genomic characteristics such as the B-cell lymphoma 6 corepressor (BCOR) upregulation and the immunoreaction of the nuclear tumor suppressor gene SMRRCB1/INI1 (INI1) were not found to be associated with a worse prognosis. SyS is one of the most common STS subtypes to express NY-ESO-1; greater than 80% of synovial tumors express NY-ESO-1, which is associated with a worse prognosis.


Synovial Sarcoma Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the synovial sarcoma market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight synovial sarcoma market report gives a thorough understanding of synovial sarcoma symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides synovial sarcoma symptoms of treatment algorithms and treatment guidelines for synovial sarcoma symptoms in the US, Europe, and Japan.


The diagnosis starts with imaging studies. X-ray, sonogram, CT scan, and MRI may be used in the course of evaluating a suspicious mass. After imaging studies, the next step in diagnosis is a biopsy to remove a tumor sample for further analysis. Among the different types of biopsies, open biopsy (a surgical incision is made to remove the sample) or core needle biopsy (a large needle is used to take the sample) are preferred. The use of a fine needle to remove cells can establish the presence of cancer, but often those cells do not provide enough tissue to characterize synovial sarcoma best.


The primary treatment for synovial sarcoma is surgery to remove the entire tumor with clear margins when possible. “Clear margins” are achieved when healthy tissue surrounding the tumor is removed along with the tumor, making it more likely that all cancer cells have been removed from the area. Depending on the location and size of the mass, it may be difficult for a surgeon to remove adequate margins around the tumor while preserving function. Radiotherapy may also be used, either before or after surgery, to reduce the risk of leaving cells behind.


Chemotherapy (typically Doxorubicin and/or Ifosfamide) might be recommended in the treatment of synovial sarcoma, especially in advanced or metastatic disease. Because synovial sarcoma is rare, there is no consensus among experts on just how much role chemotherapy plays in preventing metastases and improving survival. When developing a treatment plan, an oncologist will consider the potential benefits of chemotherapy weighed against the possible negative effects of the treatment.

Synovial Sarcoma Epidemiology

The Synovial Sarcoma symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions undertaken.


Key Findings

The total incident cases of Synovial Sarcoma is increasing by 7MM during the study period, i.e., 2018–2030.


The disease epidemiology covered in the report provides historical as well as forecasted Synovial Sarcoma symptoms epidemiology segmented as the incident cases of synovial sarcoma, gender-specific cases of synovial sarcoma, age-specific cases of synovial sarcoma, location-specific cases of synovial sarcoma, and stage-specific cases of synovial sarcoma. The report includes the incident scenario of Synovial Sarcoma symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Synovial Sarcoma Epidemiology

The epidemiology segment also provides the synovial sarcoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total number of incident cases of synovial sarcoma associated in 7MM countries was 1,610 in 2020.

Synovial Sarcoma Drug Chapters

The synovial sarcoma report’s drug chapter segment encloses the detailed analysis of synovial sarcoma early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the synovial sarcoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Synovial Sarcoma Emerging Drug


Anlotinib (AL3818): Advenchen Laboratories

AL3818 (Anlotinib; Catequentinib) is an orally administered receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). AL3818 is being evaluated for the treatment of alveolar soft part sarcoma, leiomyosarcoma, and synovial sarcoma in a global phase III trial.


ADP-A2M4: Adaptimmune Therapeutics

Adaptimmune’s ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer-testis antigens expressed in several solid tumor cell types. The MAGE- A4 antigen is among the most commonly expressed cancer-testis antigens. Adaptimmune is evaluating its affinity-enhanced SPEAR T-cells in synovial sarcoma and Myxoid/round cell liposarcoma (MRCLS).

Products detail in the report…

Synovial Sarcoma Market Outlook

The Synovial Sarcoma market outlook helps build a detailed comprehension of the historical, current, and forecasted synovial sarcoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of synovial sarcoma market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the Synovial Sarcoma market in 7MM is expected to grow in the study period 2018–2030.


Single-agent or combination chemotherapy are options for the first-line treatment of SyS. Doxorubicin, an anthracycline antibiotic, is generally considered to be the most active single agent producing objective responses in large clinical trial settings. Doxorubicin with or without ifosfamide remains the mainstay of first-line chemotherapy for synovial sarcoma treatment, although data from recent studies suggest that SyS patients can benefit from a first-line combination treatment of ifosfamide with doxorubicin over monotherapy doxorubicin. However, due to the disease’s rarity, this cannot be considered a final, conclusive result.


Compared with doxorubicin, ifosfamide has the advantage of having no dose-limiting cumulative toxicity. Also, given that it shows activity in SyS patients, ifosfamide (in high doses) is the favored second-line treatment option. Other alternative options for second-line and beyond include YONDELIS (Trabectedin) and Pazopanib (VOTRIENT) which are administered when patients relapse or fail to respond to first-line treatment options. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide.


Key Findings

This section includes a glimpse of the synovial sarcoma market in the 7MM.

The market size of synovial sarcoma in the seven major markets was USD 35.0 million in 2020.


The United States Market Outlook

This section provides the total synovial sarcoma market size and market size by therapies in the United States.

The United States accounts for the largest market size of synovial sarcoma in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


EU-5 Countries: Market Outlook

The total synovial sarcoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total synovial sarcoma market Size and market Size by therapies in Japan are also mentioned.

Synovial Sarcoma Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the synovial sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Synovial Sarcoma Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Synovial Sarcoma key players involved in developing targeted therapeutics.

Major players include Advenchen Laboratories, Adaptimmune Therapeutics, and GlaxoSmithKline.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Synovial Sarcoma emerging therapies.

Reimbursement Scenario in Synovial Sarcoma

Proactively approaching reimbursement can positively impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.


Synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCL) are the two most common translocation‐driven soft tissue sarcoma subtypes and share several important clinical and biologic features. They have a similar annual incidence rate of 800–1000 cases per year. Both SyS and MRCL occur most commonly in young adults and are often initially sensitive to chemotherapy. However, both diseases can be aggressive and have dismal outcomes in refractory metastatic settings. Overall, the median overall survival (OS) for soft tissue sarcoma is 4–18.5 months for patients treated with chemotherapy. In an analysis of seven randomized trials on first‐line chemotherapy by the European Organization for Research and Treatment of Cancer, the median survival was 51 weeks for advanced soft tissue sarcoma, and the overall response rate was 26%. For newly diagnosed patients with advanced disease, the median survival of 22 months and a response rate of 58.6% to doxorubicin plus ifosfamide were reported. In a recent study comparing doxorubicin plus evofosfamide to doxorubicin that enrolled 640 patients, the OS was 18.4 months vs. 19 months, respectively, and progression‐free survival (PFS) was 6.3 months vs. 6 months. In a separate analysis of 15 randomized clinical trials, the response to chemotherapy was 27.8% for patients with SyS vs. 18.8% for all patients, with an OS of 15.0 months for SyS vs. 11.7 months for all subjects and PFS of 6.3 months vs. 3.7 months, respectively. For SyS, the time to next treatment after progression on first‐line therapy was 8.3 months, with an OS at the time of starting second‐line treatment of 18.6%.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Synovial Sarcoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Synovial Sarcoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Synovial Sarcoma Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of synovial sarcoma, explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight has been provided into the synovial sarcoma epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for synovial sarcoma is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the synovial sarcoma market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global synovial sarcoma market.

Report Highlights

  • In the coming years, the synovial sarcoma market is set to change due to the rising awareness of the disease and the favorable environment for new anti-infective modalities, expanding the market’s size to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence synovial sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for synovial sarcoma. The launch of emerging therapies will significantly impact the synovial sarcoma market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Synovial Sarcoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Synovial Sarcoma Pipeline Analysis
  • Synovial Sarcoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Synovial Sarcoma Report Key Strengths

  • 10-years Forecast
  • 7MM Coverage
  • Synovial Sarcoma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Synovial Sarcoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the synovial sarcoma market share (%) distribution in 2018, and how would it look in 2030?
  • What would be the synovial sarcoma total market Size as well as market Size by therapies across the 7MM during the study period (2018–2030)?
  • What are the key findings of the market across 7MM, and which country will have the largest Synovial Sarcoma market Size during the study period (2018–2030)?
  • At what CAGR, the synovial sarcoma market is expected to grow by 7MM during the study period (2018–2030)?
  • What would be the synovial sarcoma market outlook across the 7MM during the study period (2018–2030)?
  • What would be the synovial sarcoma market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of synovial sarcoma?
  • What is the historical synovial sarcoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of synovial sarcoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about synovial sarcoma?
  • Out of all 7MM countries, which country would have the largest prevalent synovial sarcoma population during the study period (2018–2030)?
  • At what CAGR is the population expected to grow by 7MM during the study period (2018–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of synovial sarcoma along with the approved therapy?
  • What are the current treatment guidelines for the treatment of synovial sarcoma in the USA, Europe, and Japan?
  • What are the synovial sarcoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, and safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of synovial sarcoma?
  • How many therapies are developed by each company for the treatment of synovial sarcoma?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of synovial sarcoma?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to synovial sarcoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for synovial sarcoma and their status?
  • What are the key designations that have been granted for the emerging therapies for synovial sarcoma?
  • What are the global historical and forecasted market of synovial sarcoma?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the synovial sarcoma market.
  • To understand the future market competition in the synovial sarcoma market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for synovial sarcoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the synovial sarcoma market.
  • To understand the future market competition in the synovial sarcoma market.

1. Key Insights

2. Report Introduction

3. Synovial Sarcoma Market Overview at a Glance

3.1. Market Share (%) Distribution of Synovial Sarcoma in 2018

3.2. Market Share (%) Distribution of Synovial Sarcoma in 2030

4. Executive Summary of Synovial Sarcoma

5. Disease Background and Overview

5.1. Introduction

5.2. Soft tissue sarcoma

5.3. Signs and Symptoms

5.4. Genetics of Synovial Sarcoma

5.5. Clinical and pathologic features

5.6. Histopathologic and Immunohistochemical findings

5.7. Differential Diagnosis

5.8. Diagnosis

5.9. Treatment

5.9.1. Treatment Guidelines

5.9.2. UK Guidelines for Management of Soft-tissue Sarcomas

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Diagnosed Incident Population of Synovial Sarcoma

6.3. Epidemiology of Synovial Sarcoma

6.4. The United States

6.4.1. Incidence of Synovial Sarcoma in the United States

6.4.2. Gender-specific cases of Synovial Sarcoma in the United States

6.4.3. Age-specific cases of Synovial Sarcoma in the United States

6.4.4. Location-specific cases of Synovial Sarcoma in the United States

6.4.5. Stage-specific cases of Synovial Sarcoma in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Incidence of Synovial Sarcoma in Germany

6.5.1.2. Gender-specific cases of Synovial Sarcoma in Germany

6.5.1.3. Age-specific Cases of Synovial Sarcoma in Germany

6.5.1.4. Location-specific Cases of Synovial Sarcoma in Germany

6.5.1.5. Stage-specific Cases of Synovial Sarcoma in Germany

6.5.2. France

6.5.2.1. Incidence of Synovial Sarcoma in France

6.5.2.2. Gender-specific cases of Synovial Sarcoma in France

6.5.2.3. Age-specific Cases of Synovial Sarcoma in France

6.5.2.4. Location-specific Cases of Synovial Sarcoma in France

6.5.2.5. Stage-specific Cases of Synovial Sarcoma in France

6.5.3. Italy

6.5.3.1. Incidence of Synovial Sarcoma in Italy

6.5.3.2. Gender-specific cases of Synovial Sarcoma in Italy

6.5.3.3. Age-specific Cases of Synovial Sarcoma in Italy

6.5.3.4. Location-specific Cases of Synovial Sarcoma in Italy

6.5.3.5. Stage-specific Cases of Synovial Sarcoma in Italy

6.5.4. Spain

6.5.4.1. Incidence of Synovial Sarcoma in Spain

6.5.4.2. Gender-specific cases of Synovial Sarcoma in Spain

6.5.4.3. Age-specific Cases of Synovial Sarcoma in Spain

6.5.4.4. Location-specific Cases of Synovial Sarcoma in Spain

6.5.4.5. Stage-specific Cases of Synovial Sarcoma in Spain

6.5.5. United Kingdom

6.5.5.1. Incidence of Synovial Sarcoma in the United Kingdom

6.5.5.2. Gender-specific cases of Synovial Sarcoma in the United Kingdom

6.5.5.3. Age-specific Cases of Synovial Sarcoma in the United Kingdom

6.5.5.4. Location-specific Cases of Synovial Sarcoma in the UK

6.5.5.5. Stage-specific Cases of Synovial Sarcoma in the UK

6.6. Japan

6.6.1. Incidence of Synovial Sarcoma in Japan

6.6.2. Gender-specific cases of Synovial Sarcoma in Japan

6.6.3. Age-specific Cases of Synovial Sarcoma in Japan

6.6.4. Location-specific cases of Synovial Sarcoma in Japan

6.6.5. Stage-specific cases of Synovial Sarcoma in Japan

7. Organizations contributing towards Synovial Sarcoma

8. Patient Journey

9. Case Reports

10. Marketed Products

10.1. YONDELIS (Trabectedin): Pharma Mar SA/Johnson and Johnson

10.1.1. Product Description

10.1.2. Mechanism of action

10.1.3. Regulatory Milestones

10.1.4. Safety and Efficacy of YONDELIS

10.1.5. Product Profile

10.2. VOTRIENT (Pazopanib): Novartis Pharmaceuticals

10.2.1. Product Description

10.2.2. Mechanism of action

10.2.3. Regulatory Milestones

10.2.4. Safety and Efficacy of VOTRIENT

10.2.5. Product Profile

11. Emerging Therapies

11.1. Key Competitors

11.2. Anlotinib (AL3818): Advenchen Laboratories

11.2.1. Drug Description

11.2.2 Regulatory Milestones

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Product Profile

11.3. ADP-A2M4: Adaptimmune Therapeutics

11.3.1. Drug Description

11.3.2. Regulatory Milestones

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Safety and Efficacy

11.3.6. Product Profile

11.4. GSK3377794 (NY-ESO-1 T cells): GlaxoSmithKline

11.4.1. Drug Description

11.4.2. Regulatory Milestones

11.4.3. Clinical Development

11.4.4. Clinical Trials Information

11.4.5. Safety and Efficacy

11.4.6. Product Profile

12. Other Drugs in Development

12.1. Tazemetostat: Epizyme, Inc.

12.1.1. Drug Description

12.1.2. Regulatory Milestones

12.1.3. Clinical Development

12.1.4. Clinical Trials Information

12.1.5. Product Profile

12.2. OTSA101: OncoTherapy Science

12.2.1. Drug Description

12.2.2. Regulatory Milestones

12.2.3. Clinical Development

12.2.4. Clinical Trials Information

12.2.5. Safety and Efficacy

12.2.6. Product Profile

12.3. CAB-AXL-ADC: BioAtla

12.3.1. Drug Description

12.3.2. Regulatory Milestones

12.3.3. Clinical Development

12.3.4. Clinical Trials Information

12.3.5. Product Profile

12.4. TBI-1301: Takara Bio

12.4.1. Drug Description

12.4.2. Clinical Development

12.4.3. Clinical Trials Information

12.4.4. Product Profile

12.5. Ramucirumab: Eli Lilly and Company

12.5.1. Drug Description

12.5.2. Regulatory Milestones

12.5.3. Clinical Development

12.5.4. Clinical Trials Information

12.5.5. Product Profile

13. Synovial Sarcoma: Seven Major Market Analysis

13.1. Key Findings

13.2. Market Size of Synovial Sarcoma in the 7MM

13.3. Market Outlook

13.4. United States Market Size

13.4.1. Total Market Size of Synovial Sarcoma in the United States

13.4.2. Market Size of Synovial Sarcoma by Therapies in the United States

13.5. EU-5 Market Size

13.5.1. Germany

13.5.1.1. Total Market size of Synovial Sarcoma in Germany

13.5.1.2. Market Size of Synovial Sarcoma by Therapies in Germany

13.5.2. France

13.5.2.1. Total Market size of Synovial Sarcoma in France

13.5.2.2. Market Size of Synovial Sarcoma by Therapies in France

13.5.3. Italy

13.5.3.1. Total Market size of Synovial Sarcoma in Italy

13.5.3.2. Market Size of Synovial Sarcoma by Therapies in Italy

13.5.4. Spain

13.5.4.1. Total Market size of Synovial Sarcoma in Spain

13.5.4.2. Market Size of Synovial Sarcoma by Therapies in Spain

13.5.5. United Kingdom

13.5.5.1. Total Market size of Synovial Sarcoma in the United Kingdom

13.5.5.2. Market Size of Synovial Sarcoma by Therapies in the United Kingdom

13.6. Japan

13.6.1. Total Market size of Synovial Sarcoma in Japan

13.6.2. Market Size of Synovial Sarcoma by Therapies in Japan

14. KOL Views

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Market Access

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of Synovial Sarcoma, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Summary of ESMO recommendations

Table 3: Diagnosed Incident Population of Synovial Sarcoma in 7MM (2018–2030)

Table 4: Incidence of Synovial Sarcoma in the United States (2018–2030)

Table 5: Gender-specific cases of Synovial Sarcoma in the United States (2018–2030)

Table 6: Age-specific cases of Synovial Sarcoma in the United States (2018–2030)

Table 7: Location-specific cases of Synovial Sarcoma in the United States (2018–2030)

Table 8: Stage-specific cases of Synovial Sarcoma in the United States (2018–2030)

Table 9: Incidence of Synovial Sarcoma in Germany (2018–2030)

Table 10: Gender-specific cases of Synovial Sarcoma in Germany (2018–2030)

Table 11: Age-specific Cases of Synovial Sarcoma in Germany (2018–2030)

Table 12: Location-specific Cases of Synovial Sarcoma in Germany (2018–2030)

Table 13: Stage-specific Cases of Synovial Sarcoma in Germany (2018–2030)

Table 14: Incidence of Synovial Sarcoma in France (2018–2030)

Table 15: Gender-specific cases of Synovial Sarcoma in France (2018–2030)

Table 16: Age-specific Cases of Synovial Sarcoma in France (2018–2030)

Table 17: Location-specific Cases of Synovial Sarcoma in France (2018–2030)

Table 18: Stage-specific Cases of Synovial Sarcoma in France (2018–2030)

Table 19: Incidence of Synovial Sarcoma in Italy (2018–2030)

Table 20: Gender-specific cases of Synovial Sarcoma in Italy (2018–2030)

Table 21: Age-specific Cases of Synovial Sarcoma in Italy (2018–2030)

Table 22: Location-specific Cases of Synovial Sarcoma in Italy (2018–2030)

Table 23: Stage-specific Cases of Synovial Sarcoma in Italy (2018–2030)

Table 24: Incidence of Synovial Sarcoma in Spain (2018–2030)

Table 25: Gender-specific cases of Synovial Sarcoma in Spain (2018–2030)

Table 26: Age-specific Cases of Synovial Sarcoma in Spain (2018–2030)

Table 27: Location-specific Cases of Synovial Sarcoma in Spain (2018–2030)

Table 28: Stage-specific Cases of Synovial Sarcoma in Spain (2018–2030)

Table 29: Incidence of Synovial Sarcoma in the United Kingdom (2018–2030)

Table 30: Gender-specific cases of Synovial Sarcoma in the United Kingdom (2018–2030)

Table 31: Age-specific Cases of Synovial Sarcoma in the United Kingdom (2018–2030)

Table 32: Location-specific Cases of Synovial Sarcoma in the UK (2018–2030)

Table 33: Stage-specific Cases of Synovial Sarcoma in the UK (2018–2030)

Table 34: Incidence of Synovial Sarcoma in Japan (2018–2030)

Table 35: Gender-specific cases of Synovial Sarcoma in Japan (2018–2030)

Table 36: Age-specific Cases of Synovial Sarcoma in Japan (2018–2030)

Table 37: Location-specific cases of Synovial Sarcoma in Japan (2018–2030)

Table 38: Stage-specific cases of Synovial Sarcoma in Japan (2018–2030)

Table 39: Organization contributing to fight against synovial sarcoma

Table 40: AL3818, Clinical Trial Description, 2021

Table 41: ADP-A2M4, Clinical Trial Description, 2021

Table 42: GSK3377794, Clinical Trial Description, 2021

Table 43: Tazemetostat, Clinical Trial Description, 2021

Table 44: OTSA101, Clinical Trial Description, 2021

Table 45: CAB-AXL-ADC, Clinical Trial Description, 2021

Table 46: TBI-1301, Clinical Trial Description, 2021

Table 47: Ramucirumab, Clinical Trial Description, 2021

Table 48: 7 Major Market Size of Synovial Sarcoma in USD Million (2018–2030)

Table 49: United States Market Size of Synovial Sarcoma in USD Million (2018–2030)

Table 50: United States Market Size of Synovial Sarcoma by Therapies in USD Million (2018–2030)

Table 51: Germany Market Size of Synovial Sarcoma in USD Million (2018–2030)

Table 52: Germany Market Size of Synovial Sarcoma by Therapies in USD Million (2018–2030)

Table 53: France Market Size of Synovial Sarcoma in USD Million (2018–2030)

Table 54 : France Market Size of Synovial Sarcoma by Therapies in USD Million (2018–2030)

Table 55: Italy Market Size of Synovial Sarcoma in USD Million (2018–2030)

Table 56: Italy Market Size of Synovial Sarcoma by Therapies in USD Million (2018–2030)

Table 57: Spain Market Size of Synovial Sarcoma in USD Million (2018–2030)

Table 58: Spain Market Size of Synovial Sarcoma by Therapies in USD Million (2018–2030)

Table 59: United Kingdom Market Size of Synovial Sarcoma in USD Million (2018–2030)

Table 60: United Kingdom Market Size of Synovial Sarcoma by Therapies in USD Million (2018–2030)

Table 61: Japan Market Size of Synovial Sarcoma in USD Million (2018–2030)

Table 62: Japan Market Size of Synovial Sarcoma by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Primary Soft Tissue Tumors

Figure 2: SYT-SSX transcripts in Synovial Sarcoma

Figure 3: Management of localized, clinically resectable Soft Tissue Sarcoma (STS)

Figure 4: Management of advanced/metastatic, clinically resectable Soft Tissue Sarcoma (STS)

Figure 5: Diagnosed Incident Population of Synovial Sarcoma in 7MM (2018–2030)

Figure 6: Incidence of Synovial Sarcoma in the United States (2018–2030)

Figure 7: Gender-specific cases of Synovial Sarcoma in the United States (2018–2030)

Figure 8: Age-specific cases of Synovial Sarcoma in the United States (2018–2030)

Figure 9: Location-specific cases of Synovial Sarcoma in the United States (2018–2030)

Figure 10: Stage-specific cases of Synovial Sarcoma in the United States (2018–2030)

Figure 11: Incidence of Synovial Sarcoma in Germany (2018–2030)

Figure 12: Gender-specific cases of Synovial Sarcoma in Germany (2018–2030)

Figure 13: Age-specific Cases of Synovial Sarcoma in Germany (2018–2030)

Figure 14: Location-specific Cases of Synovial Sarcoma in Germany (2018–2030)

Figure 15: Stage-specific Cases of Synovial Sarcoma in Germany (2018–2030)

Figure 16: Incidence of Synovial Sarcoma in France (2018–2030)

Figure 17: Gender-specific cases of Synovial Sarcoma in France (2018–2030)

Figure 18: Age-specific Cases of Synovial Sarcoma in France (2018–2030)

Figure 19: Location-specific Cases of Synovial Sarcoma in France (2018–2030)

Figure 20: Stage-specific Cases of Synovial Sarcoma in France (2018–2030)

Figure 21: Incidence of Synovial Sarcoma in Italy (2018–2030)

Figure 22: Gender-specific cases of Synovial Sarcoma in Italy (2018–2030)

Figure 23: Age-specific Cases of Synovial Sarcoma in Italy (2018–2030)

Figure 24: Location-specific Cases of Synovial Sarcoma in Italy (2018–2030)

Figure 25: Stage-specific Cases of Synovial Sarcoma in Italy (2018–2030)

Figure 26: Incidence of Synovial Sarcoma in Spain (2018–2030)

Figure 27: Gender-specific cases of Synovial Sarcoma in Spain (2018–2030)

Figure 28: Age-specific Cases of Synovial Sarcoma in Spain (2018–2030)

Figure 29: Location-specific Cases of Synovial Sarcoma in Spain (2018–2030)

Figure 30: Stage-specific Cases of Synovial Sarcoma in Spain (2018–2030)

Figure 31: Incidence of Synovial Sarcoma in the United Kingdom (2018–2030)

Figure 32: Gender-specific cases of Synovial Sarcoma in the United Kingdom (2018–2030)

Figure 33: Age-specific Cases of Synovial Sarcoma in the United Kingdom (2018–2030)

Figure 34: Location-specific Cases of Synovial Sarcoma in the UK (2018–2030)

Figure 35: Stage-specific Cases of Synovial Sarcoma in the UK (2018–2030)

Figure 36: Incidence of Synovial Sarcoma in Japan (2018–2030)

Figure 37: Gender-specific cases of Synovial Sarcoma in Japan (2018–2030)

Figure 38: Age-specific Cases of Synovial Sarcoma in Japan (2018–2030)

Figure 39: Location-specific cases of Synovial Sarcoma in Japan (2018–2030)

Figure 40: Stage-specific cases of Synovial Sarcoma in Japan (2018–2030)

Figure 41: 7 Major Market Size of Synovial Sarcoma in USD Million (2018–2030)

Figure 42: Market Size of Synovial Sarcoma in the United States, USD Million (2018–2030)

Figure 43: The United States Market Size of Synovial Sarcoma by Therapies in USD Million

Figure 44: Market Size of Synovial Sarcoma in Germany, USD Million (2018–2030)

Figure 45: Germany Market Size of Synovial Sarcoma by Therapies in USD Million

Figure 46: Market Size of Synovial Sarcoma in France, USD Million (2018–2030)

Figure 47: France Market Size of Synovial Sarcoma by Therapies in USD Million

Figure 48: Market Size of Synovial Sarcoma in Italy, USD Million (2018–2030)

Figure 49: Italy Market Size of Synovial Sarcoma by Therapies in USD Million

Figure 50: Market Size of Synovial Sarcoma in Spain, USD Million (2018–2030)

Figure 51: Spain Market Size of Synovial Sarcoma by Therapies in USD Million

Figure 52: Market Size of Synovial Sarcoma in the United Kingdom, USD Million (2018–2030)

Figure 53: The United Kingdom Market Size of Synovial Sarcoma by Therapies in USD Million

Figure 54: Market Size of Synovial Sarcoma in Japan, USD Million (2018–2030)

Figure 55: Japan Market Size of Synovial Sarcoma by Therapies in USD Million

Advenchen Laboratories

Adaptimmune Therapeutics

GlaxoSmithKline

  • Tags:
  • Synovial Sarcoma market
  • Synovial Sarcoma market research
  • Synovial Sarcoma market insight
  • Synovial Sarcoma market trends
  • Synovial Sarcoma market forecast
  • Synovial Sarcoma market share
  • Synovial Sarcoma pipeline drugs
  • Synovial Sarcoma treatment algorit...
  • Synovial Sarcoma drugs
  • Synovial Sarcoma sales forecasting
  • Synovial Sarcoma market size
  • Synovial Sarcoma disease
  • Synovial Sarcoma epidemiology
  • Synovial Sarcoma

Forward to Friend

Need A Quote